The TheraBionic P1 device was approved by the FDA in September 2023 for the treatment of advanced liver cancer in adult patients for whom first- and second-line treatment therapies have failed, according to a Dec. 18 news release from the institute.
The portable device, co-invented by Karmanos President and CEO Boris Pasche, MD, PhD, targets liver cancer cell growth by delivering modulated radiofrequencies through a handheld antenna.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
